Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 68

Results For "medicines"

1265 News Found

Sonowal inaugurates SCO’s first international conference on traditional medicine
News | March 04, 2023

Sonowal inaugurates SCO’s first international conference on traditional medicine

The WHO - Global Center for Traditional Medicine will help member countries in taking enabling steps in their countries for strengthen education and practices of traditional mdicine


Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
News | March 03, 2023

Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.


ProBioGen’s growth strategy continues successfully
News | March 03, 2023

ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team


Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7
News | March 01, 2023

Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7

Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana


Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets

This combination medicine is used to treat high blood pressure (hypertension).


AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
News | March 01, 2023

AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India

Receives regulatory approval for its molecule ‘Selumetinib’ in India


NATCO launches generic Pomalidomide Capsules in Canada
News | March 01, 2023

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
Drug Approval | February 25, 2023

Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine

This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.


Pfizer’s Elranatamab receives FDA and EMA filing acceptance
Drug Approval | February 25, 2023

Pfizer’s Elranatamab receives FDA and EMA filing acceptance

Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma